Digest Network Come funziona
Network
/
Società
Ia
Non verificato

Iambic Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteTecnica

15 comunicati stampa

Guarda tutti i comunicati
21/10/2025
Mercato del lavoro
Industria
Tecnica
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Scienza
Oncologia
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0
20/10/2025
Tecnica
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Eventi
Industria
Iambic Shares Clinical Data from Ph1/1B Study of IAM1363, a Highly Selective Type-2 HER2 Inhibitor, Demonstrating Monotherapy Activity in Heavily Pretreated Patients with HER2 Alterations, at the 2025 ESMO Congress
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0
01/10/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Tecnica
Medicina - Varie
Mercato del lavoro
Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0
03/09/2025
Oncologia
Salute
Tecnica
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0
02/09/2025
Tecnica
Scienza
Medicina - Varie
Software
Biotecnologia
Salute
Farmaceutica
Eventi
Iambic to Participate in September Investor Conferences
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0
05/08/2025
Multimedialità
Salute
Tecnica
Farmaceutica
Biotecnologia
Mercato del lavoro
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0
10/06/2025
Biotecnologia
Tecnica
Salute
Sanità
Farmaceutica
Scienza
Software
Medicina - Varie
Eventi
Iambic Named to CNBC’s 2025 Disruptor 50 List
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0
04/06/2025
Eventi
Industria
Oncologia
Salute
Tecnica
Medicina - Varie
Farmaceutica
Biotecnologia
Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0
28/05/2025
Salute
Tecnica
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Iambic Therapeutics to Participate in June Investor Conferences
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0
06/01/2025
Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
Fonte
Iambic Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0